Montag & Associates’s CareDx CDNA Stock Holding History

Montag & Associates’s Portfolio CDNA Stock Details CDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-579	Closed	-$26K	–	850
2021 Q4	$26K	Buy	579 +227	+64%	+$11.8K	﹤0.01%	649
2021 Q3	$22K	Buy	+352	New	+$26.8K	﹤0.01%	661

Other funds holding CDNA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Montag & Associates's CDNA Position: Q1 2022 in Review

Montag & Associates sold out of CareDx (CDNA) in Q1 2022, closing a stake of 579 shares — an estimated $26K sold.

Montag & Associates first reported a position in CDNA in Q3 2021 and held it in 2 quarters. The position peaked at $26K in Q4 2021. 213 funds tracked by Wall St. Rank hold CDNA as of Q1 2022.

Montag & Associates reported no remaining CareDx position as of Q1 2022 after selling out during the quarter.
Montag & Associates sold 579 CareDx shares in Q1 2022, an estimated $26K.
Montag & Associates first reported a position in CareDx in Q3 2021 and held it in 2 quarters.
Montag & Associates's CareDx position peaked at $26K in Q4 2021.
213 funds tracked by Wall St. Rank held CareDx as of Q1 2022.

Based on Montag & Associates's 13F filing for Q1 2022, filed 2 May 2022.